Martin Rogers, Director PRR, was kind enough to reply on Sunday to an email from me yesterday, (which I read today after work) and to reply again tonight giving his permission for me to post it here. (Seemed unethical not to ask first)
He asked me to include a note that the information is from previous 2007 disclosed information (apart from his comment about the current USA trip, of course).
I contacted him to try to dispel some uncertainty I had about the Biomira rights and PRR's rights to CVAC and he has done so most satisfactorily. Maybe other already knew these facts, but I did not. He also volunteered some comment on the IP coverage and a positive comment about the current US trip.
This was his full reply:
"Biomira don't exist as a company anymore and the rights have been sold to Merck Sharpe & Dome.
However, Prima collapsed its relationship with Biomira swapping project ownership for shares in Prima and Prima acquired the worldwide rights for Biomira. This is a very good position for shareholders. Prima owns 100% of CVac. Biomira sold their shares a while back.
It is complex but the patents of Prima articulate the fusion of mucin-1(antigen) and mannan(carbohydrate adjunvant) to the dendritic cells presenting themselves to the immune system. This is a strong IP position to be in.
Currently I just arrived in the US, things are very positive and we should be going through a great process for shareholders over the next 18 months."
PRR Price at posting:
5.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)